Shionogi & Co., Ltd. (SGIOF) Stock Price, News & Analysis

Company Overview

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19. In addition, the company develops S-540956 for nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer's disease and fragile X syndrome; S-588410 for bladder cancer; S-488210 for head and neck squamous cell carcinoma; S-005151 for Acute ischemic stroke and epidermolysis bullosa; Rizmoic for opioid-induced constipation; ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD; S-588410 for esophageal cancer; SR-0379 for cutaneous ulcer; and S-723595 for type 2 diabetes. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.

Key Stats

• Today's Range: $16.84 to $16.84
• 50-Day Range: $15.20 to $18.05
• 52-Week Range: $12.21 to $18.05
• Volume: N/A
• Average Volume: 1,244 shs
• Market Capitalization: N/A
• P/E Ratio: 0.19
• Dividend Yield: 113.42%
• Price Target: N/A
• Consensus Rating: N/A

Shionogi & Co., Ltd. Stock Analysis - MarketRank™

Shionogi & Co., Ltd. scored higher than 5% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Shionogi & Co., Ltd..

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Shionogi & Co., Ltd. is 0.19, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.52.

Price to Earnings Ratio vs. Sector

The P/E ratio of Shionogi & Co., Ltd. is 0.19, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.41.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Shionogi & Co., Ltd. has a short interest ratio ("days to cover") of 9399, which indicates bearish sentiment.

Change versus previous month

Short interest in Shionogi & Co., Ltd. has recently decreased by 2.09%, indicating that investor sentiment is improving.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Shionogi & Co., Ltd. pays a meaningful dividend of 1.14%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Shionogi & Co., Ltd. does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Shionogi & Co., Ltd. is 21.00%. This payout ratio is at a healthy, sustainable level, below 75%.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Shionogi & Co., Ltd. has a short interest ratio ("days to cover") of 9399, which indicates bearish sentiment.

Change versus previous month

Short interest in Shionogi & Co., Ltd. has recently decreased by 2.09%, indicating that investor sentiment is improving.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Shionogi & Co., Ltd. this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Shionogi & Co., Ltd. insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 22.59% of the stock of Shionogi & Co., Ltd. is held by institutions.

SGIOF Stock Analysis - Frequently Asked Questions

How have SGIOF shares performed this year?

Shionogi & Co., Ltd.'s stock was trading at $12.21 on January 1st, 2025. Since then, SGIOF shares have increased by 37.9% and is now trading at $16.84.

How do I buy shares of Shionogi & Co., Ltd.?

Shares of SGIOF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 7/15/2025
• Next Earnings (Estimated): 7/28/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Personal Services
• Current Symbol: OTCMKTS:SGIOF
• CIK: 1281721
• Web: www.shionogi.co.jp
• Phone: (166) 202-2161
• Fax: N/A
• Employees: 5,690
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 0.19
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A